2026年10月22日 星期四 1 小时前更新 2,070 篇报道 来源 RSS

The Wire

我们阅读的各家财经媒体,汇集于此。获得授权的报道全文转载并注明作者;其余内容仅包含标题和一小段引文,直接链接至出版方。

来自 Yahoo Finance——Headlines 全部来源

简讯

Yahoo Finance 市场 全文

Here’s Why The Fund Trimmed Ross Stores (ROST) in Q2

Madison Investments, an investment advisor, released its second-quarter 2026 investor letter for the “Madison Mid Cap Fund”. You can download a copy of the letter here. U.S. stock market indices posted their strongest second-quarter…

Here’s Why The Fund Trimmed Ross Stores (ROST) in Q2

Yahoo Finance 市场 全文

Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks

Q2 13F filings show that billionaire Ken Fisher’s Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher’s fund bought 77,960 CRISPR Therapeutics shares valued at about…

Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks

Yahoo Finance 市场 全文

Robust Results Lifted Waters (WAT)

Robust Results Lifted Waters (WAT)WAT Trade Waters on Coinbase Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or…
Robust Results Lifted Waters (WAT)

Yahoo Finance 市场 全文

Is Medical Properties Trust (MPT) Finally Fixing Its Balance Sheet?

For years, Medical Properties Trust (NYSE:MPT) has operated under a cloud of debt scrutiny, prompting a careful examination of its underlying fundamentals, asset quality, and capital allocation strategy. As a specialized real estate…

Yahoo Finance 市场 全文

Can Applied Aerospace (AADX) Turn Record Backlog Into Real Profit?

In the specialized market of advanced aerospace and defense manufacturing, long-term shareholder value is fundamentally driven by multi-year program visibility, operating leverage, and disciplined portfolio expansion. Applied Aerospace &…

Can Applied Aerospace (AADX) Turn Record Backlog Into Real Profit?

Yahoo Finance 市场 全文

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency…

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
更多报道

标有全文的报道按出版方允许的条件在此转载,并注明作者、链接至原文。其余内容仅包含标题和一小段引文,直接链接至出版方。 我们如何引用 · 我们的来源